Related Experiment Video
Updated: May 2, 2026
04:01
Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma
Published on: September 15, 2023
1.4K
Radiofrequency ablation for symptomatic, non-functioning thyroid nodules: a single-center retrospective observational
Huiyin Zhu1, Lifen Bai1, Ming Zhou1
1Department of Thyroid and Breast Surgery, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Annals of Surgical Treatment and Research
|September 26, 2025
Summary
Radiofrequency ablation (RFA) effectively treats thyroid nodules (TNs), showing significant volume reduction and a high safety profile. Post-treatment nodule size decreased substantially over 12 months.
Area of Science:
- Endocrinology
- Minimally Invasive Surgery
Background:
- Thyroid nodules (TNs) are common, and while often benign, they can cause symptoms requiring treatment.
- Radiofrequency ablation (RFA) offers a minimally invasive therapeutic option for TNs.
Purpose of the Study:
- To evaluate the efficacy and safety of radiofrequency ablation (RFA) for treating thyroid nodules (TNs).
Main Methods:
- Retrospective analysis of patients undergoing RFA for TNs between January 2020 and December 2023.
- Collected preoperative and postoperative data, including thyroid hormone levels.
- Assessed RFA efficacy by measuring volume reduction (VR) and volume reduction rate (VRR) at 1, 3, 6, and 12 months post-procedure.
Main Results:
- Significant increases in volume reduction (VR) and volume reduction rate (VRR) were observed at 12 months post-RFA compared to earlier time points (P < 0.001).
- RFA demonstrated efficacy in altering nodule composition and resulted in a low incidence of postoperative complications.
Conclusions:
- Radiofrequency ablation (RFA) is a safe and effective treatment for thyroid nodules (TNs).
- The study confirms significant and progressive volume reduction of TNs following RFA treatment.
Related Concept Videos
01:20Synthesis and Regulation of Thyroid Hormones
7.1K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
7.1K
01:25Hyperthyroidism I: Introduction
30
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
30
01:27Hyperthyroidism II: Pathophysiology
28
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...
28